2017
DOI: 10.1007/s00213-017-4652-3
|View full text |Cite
|
Sign up to set email alerts
|

Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats

Abstract: Rationale Strategies to reduce the misuse of mu opioid agonists are critically needed. Previous work has shown that kappa opioid agonists can diminish the abuse-related effects and augment the antinociceptive effects of mu agonists. However, use of traditional kappa agonists is limited by their dysphoric side effects. Objectives The current study examined the effects of nalfurafine, a clinically available atypical kappa agonist, on the reinforcing, thermal antinociceptive, and respiratory depressant effects … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
55
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 51 publications
(58 citation statements)
references
References 30 publications
3
55
0
Order By: Relevance
“…The acquisition in the males was consistent with that observed using similar procedures in a group of experimentally naïve adult males (Nguyen et al, 2019). Unfortunately the majority of rat oxycodone IVSA studies published so far have been in male rats (Austin Zamarripa et al, 2018;Blackwood et al, 2019;Bossert et al, 2018;Jordan et al, 2019;Leri and Burns, 2005;Mavrikaki et al, 2019;Nawarawong et al, 2018;Neelakantan et al, 2017;Nguyen et al, 2019;Nguyen, J. D. et al, 2018b;Pravetoni et al, 2014;Townsend et al, 2017;Wade et al, 2015;You et al, 2018;You et al, 2017); one exception was a study in pregnant rats (Vassoler et al, 2018). Interestingly, when female animals were evaluated on a fentanyl dose substitution under an FR procedure, the THC exposed rats self-administered more drug at the lowest dose (Figure 9).…”
Section: Discussionsupporting
confidence: 81%
“…The acquisition in the males was consistent with that observed using similar procedures in a group of experimentally naïve adult males (Nguyen et al, 2019). Unfortunately the majority of rat oxycodone IVSA studies published so far have been in male rats (Austin Zamarripa et al, 2018;Blackwood et al, 2019;Bossert et al, 2018;Jordan et al, 2019;Leri and Burns, 2005;Mavrikaki et al, 2019;Nawarawong et al, 2018;Neelakantan et al, 2017;Nguyen et al, 2019;Nguyen, J. D. et al, 2018b;Pravetoni et al, 2014;Townsend et al, 2017;Wade et al, 2015;You et al, 2018;You et al, 2017); one exception was a study in pregnant rats (Vassoler et al, 2018). Interestingly, when female animals were evaluated on a fentanyl dose substitution under an FR procedure, the THC exposed rats self-administered more drug at the lowest dose (Figure 9).…”
Section: Discussionsupporting
confidence: 81%
“…Our study is in line with growing research into the development of biased KOP-r ligands for anti-addictive compounds [Maillet et al, 2015;White et al, 2015;Brust et al, 2016;Townsend et al, 2017].…”
Section: Kappa Opioid Receptor (Kop-r) and Dynorphin Systemsupporting
confidence: 82%
“…Recently, there is rapidly growing research into the identification of functionally selective (biased) KOP-r full agonists or partial agonists for the development of anti-addictive compounds [Maillet et al, 2015;Simonson et al, 2015;White et al, 2015;Brust et al, 2016;Schattauer et al, 2017;Townsend et al, 2017;Zhou et al, 2017a]. For a good example, Mesyl Salvinorin B (MSB), an analogue of salvinorin A, is a potent KOP-r full agonist with fewer side effects (sedation and dysphoria) compared to other "classic" KOP-r agonists [Simonson et al, 2015;Zhou et al, 2017a].…”
Section: Kappa Opioid Receptor (Kop-r) and Dynorphin Systemmentioning
confidence: 99%
“…However, in light of the current prescription opioid epidemic, we recently changed our focus to studying relapse to oxycodone, a prototypical prescription opioid drug that is widely used for pain management (Van Zee, 2009;Yaksh & Wallace, 2011). We also chose to study oxycodone because compared to heroin (Wise, 1989;Koob, 1992;Badiani et al, 2011;Bossert et al, 2013), there are very few published studies on oxycodone self-administration and relapse/reinstatement (Leri & Burns, 2005;Campbell et al, 2012;Pravetoni et al, 2014;Secci et al, 2016;Neelakantan et al, 2017;Townsend et al, 2017;You et al, 2017). Human and rodent binding studies show that oxycodone is a preferential mu opioid receptor (MOR) agonist (Lalovic et al, 2006;Peckham & Traynor, 2006) with lower affinity to MOR than morphine (Lalovic et al, 2006;Peckham & Traynor, 2006); there is also evidence that oxycodone binds to the kappa opioid receptor (KOR) (Nielsen et al, 2007).…”
Section: Introductionmentioning
confidence: 99%